Clinical Trials Details

A031704 PDIGREE (Renal)

PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III trial in Metastatic untreated RENAL Cell CANCER

Objective

Key eligibility: RCC with clear cell component; metastatic disease; intermediate or poor risk per IDMC criteria.

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms